Skip to main content
SpringerLink
Log in

Fortschritte der oralen Antibiotikatherapie in der Praxis

Progress of oral antibiotic treatment in outpatients

  • Nutzen Der Antibiotikatherapie
  • Published:
Infection Aims and scope Submit manuscript

Zusammenfassung

Einen Fortschritt in der Behandlung von Infektionen stellt jedes Antibiotikum dar, das zu einer Erhöhung der Therapiesicherheit führt. Folgende Eigenschaften muß ein neues Antibiotikum aufweisen, um einen Fortschritt gegenüber den etablierten Standardsubstanzen zu bringen: Bessere antibakterielle Aktivität, bessere pharmakokinetische und pharmakodynamische Eigenschaften, die zu einer Erhöhung der Compliance führen. Wünschenswert ist auch eine Senkung der Therapiekosten. Die häufigsten Infektionen, die in der Praxis mit oralen Antibiotika behandelt werden, sind Atemwegsinfektionen und Harnwegsinfektionen. Der Fortschritt, den die Chinolone, Kombination von Amoxicillin mit Clavulansäure, Makrolide und neuere Oralcephalosporine für die orale Antibiotikatherapie in der Praxis gebracht haben, wird diskutiert.

Summary

Any antibiotic agent that improves the safety of antibiotic treatment means progress in the management of infectious diseases. A new antibiotic has to show the following properties in order to signify progress compared to the well established antibiotics: Better antibacterial activity, better pharmacokinetic and pharmacodynamic properties, which improve patient compliance. Reduction of costs for antibiotic treatment also means progress. Infections most frequently seen in outpatients who are usually treated with oral antibiotics are respiratory and urinary tract infections. Progress in the management of infectious diseases by the introduction of quinolones, combination of amoxicillin-clavulanic acid, new macrolides and new oral cephalosporins is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Grimm, H. Aktuelle Erregerempfindlichkeit gegenüber Ciprofloxacin in Klinik und Praxis — Vergleich mit anderen Wirkstoffen. Fortschritte der Antimikrobiellen, Antineoplastischen Chemotherapie Band 8–1 (1989) 33–47.

    Google Scholar 

  2. Kresken, M., Wiedemann, B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob. Agents Chemother. 32 (1988) 1285–1288.

    Google Scholar 

  3. Pichler, H. E. T., Diridl, G., Stickler, K., Wolf, D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhoea. Am. J. Med. 82, Suppl. 4 A (1987) 329–332.

    Google Scholar 

  4. Gross, R. J., Threlfall, E. J., Ward, L. R. Drug resistance inShigella dysenteriae, S. flexneri andS. boydii in England and Wales: increasing incidence of resistance to trimethoprim. Br. Med. J. 288 (1984) 784–786.

    Google Scholar 

  5. Pichler, H. E. T., Diridl, G., Seiberl, G., Stickler, K., Wolf, D. Ciprofloxacin in the treatment of gastrointestinal infection. Int. J. Clin. practice 6, Suppl. 1 (1990) 37–43.

    Google Scholar 

  6. Doern, G. V., Jergensen, J. H., Thornsberry, C. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates ofHaemophilus influenzae. Antimicrob. Agents Chemother. 32 (1988) 180–185.

    Google Scholar 

  7. Davies, B. I., Maesen, F. P. V. Treatment ofBranhamella catarrhalis infections. J. Antimicrob. Chemotherapy 25 (1990) 1–7.

    Google Scholar 

  8. Kresken, M., Wiedemann, B. Die Epidemiologie der Resistenz bei Bakterien und ihre Bedeutung für die Wirksamkeit von Chemotherapeutika. Fortschritte der Antimikrobiellen, Antineoplastischen Chemotherapie 6 (1987) 869–1063.

    Google Scholar 

  9. Nilsen, O. G. Comparative pharmacokinetics of macrolides. J. Antimicrob. Chemotherapy 20, Suppl. B (1987) 81–88.

    Google Scholar 

  10. Foulds, G., Shepard, R. M., Johnson, R. B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemotherapy 25, Suppl. A (1990) 73–82.

    Google Scholar 

  11. Steingrimsson, O., Olafsson, J. H., Thorarinsson, H., Ryan, R. W., Johnson, R. B., Tilton, R. C. Azithromycin in the treatment of sexually transmitted disease. J. Antimicrob. Chemotherapy 25, Suppl. A (1990) 109–114.

    Google Scholar 

  12. Schönwald, S., Gunjaca, M., Kolacny-Babic, L., Car, V., Gosev, M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemotherapy 25, Suppl. A (1990) 123–126.

    Google Scholar 

  13. Maskell, J. P., Sefton, A. M., Williams, J. D. Comparativein-vitro activity of azithromycin and erythromycin against grampositive cocci,Haemophilus influenzae and anaerobes. J. Antimicrob. Chemotherapy 25, Suppl. A (1990) 19–24.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infektionsabteilung des Kaiser-Franz-Josef-Spitals, Kundratstraße 3, A-1100, Wien, Austria

    H. E. T. Pichler

Authors
  1. H. E. T. Pichler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pichler, H.E.T. Fortschritte der oralen Antibiotikatherapie in der Praxis. Infection 19 (Suppl 1), S57–S60 (1991). https://doi.org/10.1007/BF01644737

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01644737

Search

Navigation